Insulin out-of-pocket costs remained relatively flat between 2006 and 2017 among privately insured patients, despite increased insulin prices paid by insurers, according to research published in JAMA Internal Medicine.
Insulin out-of-pocket costs remained relatively flat between 2006 and 2017 among privately insured patients, despite increased insulin prices paid by insurers, according to research published in JAMA Internal Medicine.
Increased out-of-pocket costs for insulin have prompted concern in recent years, as some experts worry the practice may lead to potentially lethal rationing. The average price of a 40-day supply of insulin nearly doubled between 2012 and 2016, from $344 to $666, coming on top of costs that tripled between 2002 and 2013.
Researchers used Optum’s deidentified Clinformatics Data Mart Database to assess medical and pharmacy claims data from 612,071 privately insured Americans. Overall, 10,954,436 insulin claims were included. Members were classified based on the following health insurance benefit types: high-deductible health plan with a health savings account (HDHP-HSA), health reimbursement arrangement (HRA), or a no-account plan.
Both insulin out-of-pocket costs and reimbursement prices were analyzed. To impute insulin reimbursement price per calendar year, researchers calculated the median non-$0 deductible payment per 30-day equivalent fill of insulin prescriptions among members with an HDHP-HSA.
Investigators also “calculated insulin out-of-pocket costs per 30-day fill and per member per month to characterize the actual monthly patient costs.” They estimated the 2006 to 2017 inflation-adjusted (2017 US$) median reimbursement prices and mean out-of-pocket costs using an annual time-series design.
Of the claims included in the study, 80% (8,800,930) were from members with a no-account plan, 4% (442,662) were from those with an HRA plan, and 7% (774,903) were from individuals with an HDHP-HSA, while 9% (935,941) did not have insurance benefit design data. This cohort was excluded from the stratified analysis.
Data revealed:
Researchers found that among all insulin users, out-of-pocket costs per member per month increased from $52 (95% CI, $48-$57) in 2006 to a peak of $72 (95% CI, $70-$75) in 2013, and then decreased to $64 (95% CI, $60-$68) in 2017. In addition, “out-of-pocket costs per member per month for those with an HDHP-HSA increased from $93 (95% CI, $82-$104) in 2006 to a peak of $150 (95% CI, $144-$155) in 2014, and then decreased to $141 (95% CI, $130-$152) in 2017.”
One limitation of the study was the exclusion of uninsured or publicly insured patients and individuals who had private insurance but did not have available data. The imputed insulin price also did not account for manufacturer rebates.
“The data suggest that privately insured patients have been relatively shielded from insulin price increases and that commercial health insurers have accommodated higher insulin prices by increasing premiums or deductibles for all members,” the authors concluded.
Reference
Meiri A, Zhang F, Ross-Degnan D, et al. Trends in insulin out-of-pocket costs and reimbursement price among US patients with private health insurance, 2006-2017. JAMA Intern Med. Published online June 1, 2020. doi:10.1001/jamainternmed.2020.1302
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More